  A case report of fatal disseminated cryptococcosis in a patient treated with eculizumab is presented along with a review of literature suggesting a possible etiologic mechanism. A 23-year-old man with a history of minimal change nephrotic syndrome<disease> was hospitalized for acute kidney injury and abdominal<symptom> pain<symptom> and swelling. He was found to have disseminated pneumococcal disease , including peritonitis<disease> , bacteremia , and pulmonic endocarditis<disease> The patient developed evidence of microangiopathic<symptom> hemolytic<symptom> anemia<symptom> , leading to a diagnosis of atypical hemolytic uremic syndrome<disease> , and was started on eculizumab. The patient initially improved but developed septic shock<symptom> 18 days after the first dose of eculizumab. All subsequent blood , respiratory , and intraabdominal cultures grew A 23-year-old man developed fatal disseminated cryptococcosis after treatment with eculizumab.